| Naomi R George, MD | |
|
593 Eddy St, Providence, RI 02903 | |
| (401) 444-4000 | |
| Not Available |
| Full Name | Naomi R George |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 12 Years |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568723526 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Unm Sandoval Regional Medical Center | Rio rancho, NM | Hospital |
| University Of New Mexico Hospital | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of New Mexico Medical Group | 4981795267 | 1002 |
News Archive
Cardiac surgeons are successfully performing more extensive surgical repairs of type A aortic dissection — one of the highest risk operations in cardiothoracic surgery.
Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.
Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and increasing the scale and efficiency of viral vector manufacturing.
Latest research from Affirmativ Health succeeds in treating cognitive decline using personalized, precision medicine.
› Verified 2 days ago
| Entity Name | Unm Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831218627 PECOS PAC ID: 4981795267 Enrollment ID: O20070801000589 |
News Archive
Cardiac surgeons are successfully performing more extensive surgical repairs of type A aortic dissection — one of the highest risk operations in cardiothoracic surgery.
Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.
Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and increasing the scale and efficiency of viral vector manufacturing.
Latest research from Affirmativ Health succeeds in treating cognitive decline using personalized, precision medicine.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Naomi R George, MD Po Box 9484, Providence, RI 02940-9484 Ph: (401) 854-2500 | Naomi R George, MD 593 Eddy St, Providence, RI 02903 Ph: (401) 444-4000 |
News Archive
Cardiac surgeons are successfully performing more extensive surgical repairs of type A aortic dissection — one of the highest risk operations in cardiothoracic surgery.
Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.
Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and increasing the scale and efficiency of viral vector manufacturing.
Latest research from Affirmativ Health succeeds in treating cognitive decline using personalized, precision medicine.
› Verified 2 days ago
Dr. Robert A Partridge, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Claverick 2, Providence, RI 02903 Phone: 401-519-1604 Fax: 401-272-0538 | |
Dr. Gregory R Lockhart, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Claverick 2, Providence, RI 02903 Phone: 401-444-4000 Fax: 401-427-7795 | |
Ian M Jacobson, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 330-493-4443 | |
Dr. Daniel Shanin, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St., Claverick 2, Providence, RI 02903 Phone: 401-444-4000 | |
Carli Renske Reisdorf, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-6680 | |
Dr. Oriane Diana Longerstaey, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Providence, RI 02906 Phone: 704-355-3181 | |
Rachel Smith Shain, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-6489 Fax: 401-444-6662 |